Iso­Plex­is bags $25M to stoke T cell ther­a­py buzz; Col­lab­o­ra­tion be­tween X4 and LLS; New CMO at Pre­ci­sion Bio­sciences

→ Rid­ing on the buzz around T cell ther­a­pies from CAR-T and TCR to CRISPR-based ap­proach­es, Iso­Plex­is has raised $25 mil­lion to ad­vance its bio­mark­er-dri­ven sys­tem de­signed to pre­dict re­spons­es to such treat­ments. The Bran­ford, Con­necti­cut-based com­pa­ny works with can­cer cen­ters and bio­phar­ma com­pa­nies in the US, Eu­rope and Chi­na, ap­ply­ing its sin­gle-cell analy­sis tool to re­fine their im­munother­a­pies. North­pond Ven­tures led the Se­ries C, which al­so fea­tured ex­ist­ing in­vestors Spring Moun­tain Cap­i­tal, Iron­wood Cap­i­tal, North Sound Ven­tures, and Con­necti­cut In­no­va­tions.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER